NCT05706129招募中1 期
A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 270
- 试验地点
- 19
- 主要终点
- Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) [maximum tolerated dose (MTD) or lower dose] for [177Lu]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of [177Lu]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between [68Ga]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess [68Ga]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Part A, B, and C:
- •Written informed consent, dated and signed by the patient prior to any study-specific procedure.
- •Part B and C are not conducted in the United States of America.
- •Has histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- •Clear cell renal cell cancer (ccRCC) - participants must have received at least one line containing Tyrosine kinase inhibitor (TKI) treatment and at least one line containing immune checkpoint inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting.
- •Pancreatic ductal adenocarcinoma (PDAC) - participants must have received at least one line of platinum- and/or gemcitabine-based regimen.
- •Colorectal cancer (CRC) - participants must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-Vascular Endothelial Growth Factor (VEGF) or anti-Epidermal Growth Factor Receptor (EGFR).
- •Participants with CRC or PDAC: availability of fresh biopsy, OR an archival biopsy/surgical specimen of the tumor (preferably, taken after last prior line of therapy).
- •For Part B and C only: Urothelial cancer (UC) patients must have received all available standard of care if eligible, including one line of platinum-based chemotherapy, enfortumab vedotin and pembrolizumab.
- •Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (computed tomography / magnetic resonance imaging (CT/MRI)) documented within 4 weeks prior to the [68Ga]Ga-DPI-4452 administration.
- •Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.
- •Participants with imaging evidence of a single indeterminate renal mass (IDRM) of ≤ 7 cm in largest diameter (tumor stage cT1) on any conventional diagnostic imaging technique, suspicious for ccRCC and planned for total or partial nephrectomy, or interventional diagnostic (cystoscopy and retrograde pyelography or biopsy) within 90 days from planned [68Ga]Ga-DPI-4452 administration.
- •Regardless of lines of treatment, participants with histologically or cytologically confirmed progressive, unresectable locally advanced or metastatic solid tumors of
- •UC, including MIBC
- •H&N cancer
- •Squamous NSCLC
- •Any other indication with confirmed carbonic anhydrase IX (CA IX) expression excluding ccRCC, PDAC and CRC, upon Sponsor agreement.
- •Presence of at least 1 non-irradiated tumor lesion detected at conventional imaging (CT/MRI) documented within 4 weeks prior to the [68Ga]Ga-DPI-4452 administration (for scans dated more than 4 weeks prior to D1, the Sponsor should be contacted to assess conventional imaging suitability)
排除标准
- •Any major surgery within 12 weeks before enrolment.
- •Inability to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan.
- •Has known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
- •Bladder outflow obstruction or unmanageable urinary incontinence.
- •Participants who have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and/or stable Grade 2 sensory neuropathy, according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE]).
- •Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-
- •Previous Carbonic anhydrase (CA) IX-targeting treatment.
- •Prior external beam radiation therapy (EBRT) to more than 25% of the bone marrow, as judged by the Investigator.
- •Part B and Part C:
- •Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
- •Bladder outflow obstruction or unmanageable urinary incontinence.
- •Participants who have not had resolution of clinically significant toxic effects of prior systemic cancer therapy, surgery, active clinically significant cardiac disease, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, or stable Grade 2 sensory neuropathy, according to NCI-CTCAE).
- •Administration of a radiopharmaceutical with therapeutic intent within a period of 6 months prior to injection of [68Ga]Ga-DPI-
- •Any previous CA IX-targeting treatment for non-oncological indication within 3 months prior to the [177Lu]Lu-DPI-4452 infusion; any previous CA IX-targeting treatment for any oncological indication.
- •Participants who received any systemic antineoplastic therapy for the underlying disease and/or other investigational agents within a period which is ≤5 half-lives or ≤4 weeks (whichever is shorter).
- •Inflammatory bowel disease (e.g Crohn's disease, ulcerative colitis, etc).
- •Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
- •Any previous CA IX-targeting treatment within 3 months prior to the [68Ga]Ga-DPI-4452 injection.
- •Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-
- •Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which participants are not on active antineoplastic therapy.
- •Ongoing treatment with sulfonamides and/or coumarin derivatives (e.g., acenocoumarol, warfarin, phenprocoumon) within 2 weeks (or 5 half-lives, whichever is longer) prior to the [68Ga]Ga-DPI-4452 injection.
- •Known hypersensitivity to the active substance, to any of the excipients of the DPI-4452, or to radiographic contrast agents.
- •Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of [68Ga]Ga-DPI-
- •Any previous CA IX-targeting treatment within 3 months prior to [68Ga]Ga-DPI-4452 injection.
- •EBRT to more than 25% of the bone marrow, as judged by the Investigator.
- •Malignant disease, other than that being treated in this study. Exceptions include the following: malignancies that were treated curatively and have not recurred within 2 years prior to screening; treated basal cell or localized squamous skin carcinomas, localized or low grade (e.g., Gleason 3+3 or 3+4 with low prostate specific antigen) prostate cancer, superficial (non-muscle invasive) urothelial cancer, localized thyroid gland microcarcinoma, other in-situ carcinoma, or other malignancy for which participants are not on active antineoplastic therapy.
- •Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.
研究组 & 干预措施
Part C: [177Lu]Lu-DPI-4452
Experimental
Participants will receive a single dose of [68Ga]Ga-DPI-4452, at screening and RP2D dose of [177Lu]Lu-DPI-4452, on Day 1 of each cycle (Q4W or Q6W) the treatment period.
干预措施: [68Ga]Ga-DPI-4452 (Drug)
Part C: [177Lu]Lu-DPI-4452
Experimental
Participants will receive a single dose of [68Ga]Ga-DPI-4452, at screening and RP2D dose of [177Lu]Lu-DPI-4452, on Day 1 of each cycle (Q4W or Q6W) the treatment period.
干预措施: [177Lu]Lu-DPI-4452 (Drug)
Part E: [68Ga]Ga-DPI-4452
Experimental
Participants will receive [68Ga]Ga-DPI-4452, a single dose on Day 1.
干预措施: [68Ga]Ga-DPI-4452 (Drug)
Part B: [177Lu]Lu-DPI-4452
Experimental
Participants will receive a single dose of [68Ga]Ga-DPI-4452, at screening then escalating doses of [177Lu]Lu-DPI-4452, on Day 1 of each (Q4W or Q6W) cycle and RP2D will be determined.
干预措施: [177Lu]Lu-DPI-4452 (Drug)
Part B: [177Lu]Lu-DPI-4452
Experimental
Participants will receive a single dose of [68Ga]Ga-DPI-4452, at screening then escalating doses of [177Lu]Lu-DPI-4452, on Day 1 of each (Q4W or Q6W) cycle and RP2D will be determined.
干预措施: [68Ga]Ga-DPI-4452 (Drug)
Part A: [68Ga]Ga-DPI-4452
Experimental
Participants will receive [68Ga]Ga-DPI-4452, a single dose on Day 1.
干预措施: [68Ga]Ga-DPI-4452 (Drug)
Part D: [68Ga]Ga-DPI-4452
Experimental
Participants will receive [68Ga]Ga-DPI-4452, a single dose on Day 1.
干预措施: [68Ga]Ga-DPI-4452 (Drug)
结局指标
主要结局
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
时间窗: Up to Day 7
Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
时间窗: Cycle 1(each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks dosing schedule)
Part C: Objective Response Rate (ORR)
时间窗: Up to 81 months
Part D: Concordance Between [68Ga]Ga-DPI-4452 Uptake by PET Imaging and Assessment of Histological Characteristics of IDRM
时间窗: Day 1
Part E: Radiotracer Uptake at Lesion Level Identified by PET Imaging
时间窗: Day 1
次要结局
- Parts B and C: Duration of Response (DoR)(Up to 81 months)
- Parts B and C: Disease Control Rate (DCR)(Up to 81 months)
- Parts A, B, and C: Concentration of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Urine(Part A: Pre-dose and at multiple time points up to 4 hours post-dose on Day 1; Parts B and C: Pre-dose and at multiple time points up to 48 hours post-dose of Cycle 1 (each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks dosing schedule))
- Part A: Radioligand [68Ga]Ga-DPI-4452 PET Scan Time-Window for Optimal Imaging(Day 1)
- Parts B, C, D, and E: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(Up to 81 months)
- Part B: Objective Response Rate (ORR)(Up to 81 months)
- Part A, B, and C: Concentration of [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in Blood and Plasma(Part A: Pre-dose and at multiple time points up to 4 hours post-dose on Day 1; Parts B and C: Pre-dose and at multiple time points up to 72 hours post-dose of Cycles 1, 2 and 3 (84 days) (each cycle = 28 or 42 days depending on every 4 weeks or 6 weeks))
- Parts B and C: Progression Free Survival (PFS) Rate at 6 Months(6 months)
- Parts B and C: Progression Free Survival (PFS)(Up to 81 months)
- Parts B and C: Overall Survival (OS)(Up to 81 months)
- Part D: Assessment of Diagnostic Accuracy of [68Ga]Ga-DPI-4452 PET imaging(Day 1)
- Parts A, B, C, and E: Number of Positive Tumor Lesions Detected by Imaging(Part A and E: Day 1; Part B and C: Baseline)
- Parts A, B, and C: Dosimetry [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452(Part A: Day 1; Parts B and C: Cycle 1 (each cycle= 28 days))
研究者
研究点 (19)
Loading locations...
相似试验
已完成
1 期
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)LymphomaNCT00517530Hoffmann-La Roche134
已完成
1 期
Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive DiseasePeripheral Arterial Occlusive DiseaseNCT01157156Sanofi51
终止
1 期
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy VolunteersHealthy VolunteersNCT06435039Syneos Health12
进行中（未招募）
1 期
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Advanced or Metastatic Solid TumorsNCT05382325Merck Sharp & Dohme LLC70
终止
1 期
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101Advanced Solid TumorsLymphomaNCT04144140Eisai Inc.24
相关资讯
ITM Receives FDA Fast Track Designation for ITM-94 Diagnostic Agent in Clear Cell Renal Cell Carcinoma- ITM Isotope Technologies Munich SE received FDA Fast Track designation for ITM-94, a gallium-68-radiolabeled PET imaging agent designed for non-invasive detection of clear cell renal cell carcinoma.
- ITM-94 forms a first-in-class theranostic pair with therapeutic candidate ITM-91, both targeting carbonic anhydrase IX (CAIX) protein in the tumor microenvironment.
- The diagnostic agent is currently being evaluated in a Phase 1/2 clinical trial for detecting ccRCC in patients with indeterminate renal masses compared to CT/MRI imaging.
- Fast Track designation enables more frequent FDA communications during development and potential accelerated approval for this unmet medical need in cancer diagnosis.10 months agoITM and Debiopharm Initiate New Study Arm for CAIX-Targeted Theranostic in Clear Cell Renal Cell Carcinoma- ITM and Debiopharm announced the first patient imaging in Part D of their Phase 1/2 trial evaluating ITM-94 as a diagnostic agent for clear cell renal cell carcinoma.
- The study will assess ITM-94's effectiveness in classifying indeterminate renal masses as cancerous or non-cancerous, enrolling approximately 36 patients across 15 clinical sites.
- ITM-94 demonstrated exceptional imaging characteristics in Part A, with high tumor-to-background ratios and ability to detect lesions not visible by CT scan.
- The theranostic pair ITM-91/ITM-94 targets CAIX, which is overexpressed in more than 90% of clear cell renal cell carcinoma cases.last year